Skip to main content
. 2021 Aug 18;11:704336. doi: 10.3389/fonc.2021.704336

Figure 1.

Figure 1

First-Line ICI Immunotherapy for Lung Cancer. In the first-line ICI immunotherapy of lung cancer, for metastatic NSCLC patients with PD-L1 ≥50% without TKI mutation, pembrolizumab monotherapy is preferred. For metastatic NSCLC patients with PD-L1 1%–49% who are intolerable or unacceptable to chemotherapy, pembrolizumab monotherapy may be considered. Regardless of PD-L1 level, for metastatic non-squamous NSCLC patients without TKI mutation, pembrolizumab/chemotherapy is preferred or ABCP regimen may be considered. Regardless of PD-L1 level, for metastatic squamous NSCLC patients, carboplatin/paclitaxel/pembrolizumab regimen is preferred. Regardless of PD-L1 level, for metastatic SCLC patients, atezolizumab or durvalumab/EP chemotherapy is preferred. ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; ABCP, atezolizumab/bevacizumab/carboplatin/paclitaxel; EP, etoposide/platinum.